Antengene has dosed the first subject in a Phase I/II HATCH trial of eltanexor (ATG-016) for treating patients with intermediate and higher-risk myelodysplastic syndrome (MDS) in China.
A selective inhibitor of nuclear export compound, eltanexor stimulates apoptosis in tumour cells by hindering nuclear export protein XPO1.
The single-arm, open-label HATCH trial will assess the safety and efficacy of eltanexor as a single agent in MDS patients who had failed hypomethylating agent (HMA) based treatments.
According to results from a Phase I/II clinical trial in increased-risk MDS patients who are refractory to HMAs, eltanexor provided an objective response rate (ORR) of 35%, with all of them achieving bone marrow complete response.
Furthermore, eltanexor was found to have favourable safety and tolerability profile in the trial.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataApart from MDS, eltanexor is being analysed for treating advanced solid tumour patients in China.
Antengene founder, chairman and CEO Dr Jay Mei said: “We are encouraged by the dosing of the first MDS patient in the HATCH trial, as it marks the beginning of the clinical development of our second SINE compound.
“Eltanexor was found to be safe and well-tolerated in preclinical studies and showed potent anti-cancer activity in xenograft models, and demonstrated preliminary clinical efficacy and well-tolerated safety profile in patients with high-risk MDS.”
MDS is a malignancy that develops in the bone marrow hemopoietic stem cells and its incidence rises drastically with age.
The median overall survivals (OS) of intermediate, high, and very high-risk MDS patients are 3, 1.6, and 0.8 years, respectively. They are also at an increased risk of advancing to acute myeloid leukaemia.
HMAs such as azacytidine and decitabine are used as standard of care therapies for MDS but they do not eliminate neoplastic clones and cause a response in nearly 50% of MDS patients, Antengene noted.
In addition, MDS patients who are refractory to HMA-based treatments have a reduced prognosis, fewer options for follow-up therapies and a median OS of just four to six months.
In November last year, Antengene announced plans to begin the Phase I/II clinical trial of eltanexor monotherapy in patients with intermediate and higher-risk MDS.
